SCHEDULE: Frazier Life Sciences Amends Palvella Therapeutics Stake
Beneficial Ownership Report
Frazier Life Sciences funds updated their beneficial ownership in Palvella Therapeutics, Inc., reporting a 6.0% stake for its Public Fund.
Summary
- Frazier Life Sciences Public Fund, L.P. (FLSPF) and its related entities (FHMLSP, L.P. and FHMLSP, L.L.C.) beneficially own 706,360 shares of Palvella Therapeutics, Inc. Common Stock, representing 6.0% of the class.
- These shares were acquired from Frazier Life Sciences Public Overage Fund, L.P. pursuant to a merger.
- Frazier Life Sciences X, L.P. (FLS X) and its related entities (FHMLS X, L.P., FHMLS X, L.L.C., James N. Topper, Patrick J. Heron) beneficially own 4,730 shares, representing 0.0% of the class.
- Frazier Life Sciences XI, L.P. (FLS XI) and its related entities (FHMLS XI, L.P., FHMLS XI, L.L.C.) beneficially own 7,517 shares, representing 0.1% of the class.
- Frazier Life Sciences XII, L.P. (FLS XII) and its related entities (FHMLS XII, L.P., FHMLS XII, L.L.C.) beneficially own 3,793 shares, representing 0.0% of the class.
- The percentages are calculated based on 11,836,490 shares of Common Stock outstanding as of November 7, 2025.
- The reporting persons also hold warrants to purchase additional shares, subject to a 4.99% beneficial ownership limitation upon exercise. Specifically, FLSPF holds warrants for 1,214,731 shares, FLS X for 5,641 shares, and FLS XI for 5,886 shares.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a routine disclosure of beneficial ownership by an institutional investor group, providing factual information without indicating positive or negative operational developments for Palvella Therapeutics.
Future Outlook
NA
Industry Context
StockSavvy.ai notes that institutional investors like Frazier Life Sciences frequently adjust their stakes in biotechnology companies such as Palvella Therapeutics, reflecting ongoing portfolio management and strategic investment decisions within the life sciences sector. This filing is a routine disclosure of such adjustments.
Stakeholder Impact
- Shareholders: Provides transparency regarding significant institutional ownership, which can influence market perception and trading liquidity.
Key Dates
| Date | Description |
|---|---|
| November 7, 2025 | Date on which 11,836,490 shares of Common Stock were outstanding, as reported in the Issuer's 10-Q. |
| November 12, 2025 | Date the Issuer's Quarterly Report on Form 10-Q was filed with the SEC. |
| December 31, 2025 | Date of event which requires filing of this statement (reporting period end). |
| January 27, 2026 | Date a Power of Attorney for James N. Topper and Patrick J. Heron was filed with the SEC. |
| February 13, 2026 | Date of filing this Schedule 13G. |
Keywords
Palvella Therapeutics, Frazier Life Sciences, Schedule 13G, beneficial ownership, common stock, institutional investor, SEC filing, equity stake, investment fund, biotech, pharmaceutical
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.